Deep 6 AI, the leader in AI-powered patient recruitment and real-world data (RWD), together with Magnolia Market Access, a provider of tailored RWD insights and strategies for market access, health economics and outcomes research (HEOR), and healthcare policy, today announced a partnership to accelerate stakeholder decision-making across the pharmaceutical, biologic, and medical device product lifecycle. The combined RWE generation solution uses AI to develop fit-for-purpose, analysis-ready clinical data sets from electronic medical record (EMR) data months faster than traditional approaches.
Typically, it can take life sciences companies a year or more to contract with healthcare organizations to gain access to EMR data. Site staff then shoulder the burden of manually identifying and pulling potentially eligible patient charts. The offering from Deep 6 AI and Magnolia Market Access uses AI to instantly and precisely find patients that are eligible for research within Deep 6 AI’s established site ecosystem and abstract relevant data from their charts. This reduces the time it takes to access EMR data and lowers the burden on site staff.
„The power of the Deep 6 AI technology is that it connects life sciences companies with 25+ major healthcare organizations that have our AI integrated within their provider workflows to accelerate collaboration on RWD projects, saving time and resources for all stakeholders,“ said Wout Brusselaers, Founder and CEO of Deep 6 AI.
Deep 6 AI’s software precisely identifies matched patient cohorts across its ecosystem by querying the entire EMR in real time, including coded data, free-text clinician notes, omics, lab results, and radiology, pathology, and operative reports—accessing 80% more data than solutions that mine structured data alone.
Foto credits: Deep 6 AI
https://deep6.ai/solutions/rwe-generation/
